| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Immunology, Beckman Research Institute, City of Hope, Duarte, CA 91010; and
Department of Pathology, University of Florida College of Medicine, Gainesville, FL 32610
Immunization of NOD mice with autoantigens such as glutamic acid decarboxylase (GAD) 221–235 peptide (p221) can induce Ag-specific CD4+ T regulatory (Tr) cells. However, it is unclear whether these Tr cells acquire their regulatory capacity due to immunization or whether they are constitutively harbored in unimmunized naive mice. To address this question, we used an I-Ag7 tetramer to isolate p221-specific T cells from naive NOD mice (N221+ cells) after peptide-specific in vitro expansion. The N221+ T cells produced IFN-
and IL-10, but very little IL-4, in response to p221 stimulation. These T cells could function as regulatory cells and inhibit in vitro proliferation of diabetogenic BDC2.5 cells. This suppressive activity was cell contact-independent and was abrogated by Abs to IL-10 or IL-10R. Interestingly, IL-2 produced by other T cells present in the cell culture induced unactivated N221+ T cells to exhibit regulatory activities involving production of IL-10. In vivo, N221+ cells inhibited diabetes development when cotransferred with NOD splenocytes into NOD/scid recipients. Together, these results demonstrate that p221-specific IL-10-dependent Tr cells, including Tr type 1 cells, are present in naive NOD mice. The use of spontaneously arising populations of GAD peptide-specific Tr cells may represent a promising immunotherapeutic approach for preventing type 1 diabetes.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  L. Li, Z. Yi, B. Wang, and R. Tisch Suppression of Ongoing T Cell-Mediated Autoimmunity by Peptide-MHC Class II Dimer Vaccination J. Immunol., October 1, 2009; 183(7): 4809 - 4816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Gebe, B. B. Yue, K. A. Unrath, B. A. Falk, and G. T. Nepom Restricted Autoantigen Recognition Associated with Deletional and Adaptive Regulatory Mechanisms J. Immunol., July 1, 2009; 183(1): 59 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. You, B. Leforban, C. Garcia, J.-F. Bach, J. A. Bluestone, and L. Chatenoud Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment PNAS, April 10, 2007; 104(15): 6335 - 6340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, W.-h. Lee, L. Zhong, and C.-P. Liu Regulatory T Cells Can Mediate Their Function through the Stimulation of APCs to Produce Immunosuppressive Nitric Oxide J. Immunol., March 15, 2006; 176(6): 3449 - 3460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yang, N. A. Danke, D. Berger, S. Reichstetter, H. Reijonen, C. Greenbaum, C. Pihoker, E. A. James, and W. W. Kwok Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein-Reactive CD4+ T Cells in Human Subjects. J. Immunol., March 1, 2006; 176(5): 2781 - 2789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Mu, X. Ouyang, A. Agarwal, L. Zhang, D. A. Long, P. E. Cruz, C. A. Roncal, O. Y. Glushakova, V. A. Chiodo, M. A. Atkinson, et al. IL-10 Suppresses Chemokines, Inflammation, and Fibrosis in a Model of Chronic Renal Disease J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3651 - 3660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Olcott, J. Tian, V. Walker, H. Dang, B. Middleton, L. Adorini, L. Washburn, and D. L. Kaufman Antigen-Based Therapies Using Ignored Determinants of {beta} Cell Antigens Can More Effectively Inhibit Late-Stage Autoimmune Disease in Diabetes-Prone Mice J. Immunol., August 1, 2005; 175(3): 1991 - 1999. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
